DE60320784D1 - Stände zur modulierung des knochenwachstums - Google Patents
Stände zur modulierung des knochenwachstumsInfo
- Publication number
- DE60320784D1 DE60320784D1 DE60320784T DE60320784T DE60320784D1 DE 60320784 D1 DE60320784 D1 DE 60320784D1 DE 60320784 T DE60320784 T DE 60320784T DE 60320784 T DE60320784 T DE 60320784T DE 60320784 D1 DE60320784 D1 DE 60320784D1
- Authority
- DE
- Germany
- Prior art keywords
- bone growth
- stands
- bone
- modulating
- modulating bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000008468 bone growth Effects 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108050007331 Cannabinoid receptor Proteins 0.000 abstract 1
- 210000002449 bone cell Anatomy 0.000 abstract 1
- 230000010072 bone remodeling Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003405 preventing effect Effects 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38588102P | 2002-06-06 | 2002-06-06 | |
US41027602P | 2002-09-13 | 2002-09-13 | |
PCT/IL2003/000480 WO2004103410A1 (en) | 2002-06-06 | 2003-06-08 | Methods compositions and articles of manufacture for modulating bone growth |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60320784D1 true DE60320784D1 (de) | 2008-06-19 |
Family
ID=33479219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60320784T Expired - Lifetime DE60320784D1 (de) | 2002-06-06 | 2003-06-08 | Stände zur modulierung des knochenwachstums |
Country Status (7)
Country | Link |
---|---|
US (2) | US7749953B2 (de) |
EP (1) | EP1509250B1 (de) |
JP (1) | JP2006517194A (de) |
AT (1) | ATE394124T1 (de) |
AU (1) | AU2003233172A1 (de) |
DE (1) | DE60320784D1 (de) |
WO (1) | WO2004103410A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7024027B1 (en) * | 2001-11-13 | 2006-04-04 | Koninklijke Philips Electronics N.V. | Method and apparatus for three-dimensional filtering of angiographic volume data |
ATE394124T1 (de) * | 2002-06-06 | 2008-05-15 | Yissum Res Dev Co | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums |
JP4719469B2 (ja) * | 2002-12-19 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 置換アミド類 |
US7407753B2 (en) | 2004-05-24 | 2008-08-05 | Yissum Research Development Company Of The Hebrewuniversityofjerusalem | Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis |
NO20053519L (no) * | 2005-07-18 | 2007-01-19 | Thia Medica As | Anvendelse av forbindelser som omfatter fettsyrer |
WO2008001369A1 (en) * | 2006-06-27 | 2008-01-03 | Pharmos Corporation | Use of cb2 receptor agonists for promoting neurogenesis |
WO2008033501A2 (en) * | 2006-09-14 | 2008-03-20 | Spineology, Inc. | Absorbent fabric implant |
JP5829400B2 (ja) * | 2008-01-24 | 2015-12-09 | レメドー バイオメッド リミテッド | 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物 |
GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
WO2010041253A1 (en) | 2008-10-06 | 2010-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions comprising cb receptor agonists, uses thereof and methods for their preparation |
TWI443337B (zh) * | 2008-10-10 | 2014-07-01 | Ct Hospitalier Universitaire Sainte Justine | 用於脊柱側彎之分類及診斷的方法 |
US8541386B2 (en) * | 2009-08-19 | 2013-09-24 | University Of South Florida | Cannabinoid 2 (CB2) receptor gene promoter and unique RNA transcripts in B cells and methods of use |
WO2016080813A1 (en) * | 2014-11-21 | 2016-05-26 | Samsung Electronics Co., Ltd. | Method and apparatus for processing medical image |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
KR102002817B1 (ko) * | 2017-10-25 | 2019-07-23 | 주식회사 시티오브테크 | 방수 아스콘 첨가제 및 그 제조방법, 방수 아스콘 및 그 제조방법 그리고, 방수 아스콘 시공방법 |
BR112020024210A2 (pt) * | 2018-05-31 | 2021-02-17 | Corbus Pharmaceuticals, Inc. | canabinoides e seus usos |
US11793452B2 (en) | 2019-10-03 | 2023-10-24 | Johnson & Johnson Consumer Inc. | Method of visualizing and quantifying remineralization |
KR20220138990A (ko) * | 2021-04-07 | 2022-10-14 | 주식회사 스템바이오 | 우유 유래 세포외소포체를 포함하는 골형성 촉진용 조성물 |
CN114748604B (zh) * | 2022-05-10 | 2023-04-07 | 四川大学 | 一种用于骨髓损伤和/或抑制的复合物 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5068234A (en) | 1990-02-26 | 1991-11-26 | Sterling Drug Inc. | 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles |
CA2040264A1 (en) | 1990-04-12 | 1991-10-13 | Tatsuhiko Kanmera | Parathyroid hormone antagonists |
US5225925A (en) | 1991-01-23 | 1993-07-06 | Amoco Corporation | Sensitized erbium fiber optical amplifier and source |
US5208219A (en) | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
EP0499242B1 (de) | 1991-02-15 | 1996-06-26 | Takeda Chemical Industries, Ltd. | Mit einem Zellwachstumsfaktor bewirkte Anregung von Wachstum im Knocheninneren |
FR2673852B1 (fr) | 1991-03-13 | 1994-04-15 | Labinal Precision Mecanique | Perfectionnements apportes aux cartouches de filtration comprenant un element filtrant constitue par une feuille plissee. |
IL101927A0 (en) | 1992-05-19 | 1992-12-30 | Yissum Res Dev Co | Probe for cannabinoid receptors |
IL103932A (en) | 1992-11-30 | 1997-02-18 | Yissum Res & Dev | Fatty acid and pharmaceutical compositions containing them |
US6352972B1 (en) | 1995-06-06 | 2002-03-05 | Marcel E. Nimni | Bone morphogenetic proteins and their use in bone growth |
US6352973B1 (en) | 1995-06-07 | 2002-03-05 | Osteopharm Inc. | Bone stimulating factor |
US6008208A (en) | 1995-10-23 | 1999-12-28 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
US6440421B1 (en) | 1996-04-18 | 2002-08-27 | Auchkland Uniservices Limited | Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
US5688825A (en) | 1996-05-31 | 1997-11-18 | University Of Connecticut | Anandamide amidase inhibitors as analgesic agents |
EP0971588B1 (de) * | 1997-01-21 | 2004-03-17 | Smithkline Beecham Corporation | Neue cannabinoidrezeptor-modulatoren |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
DE19706903A1 (de) | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
WO1998041519A1 (en) * | 1997-03-18 | 1998-09-24 | Smithkline Beecham Corporation | Novel cannabinoid receptor agonists |
WO1999026612A1 (en) * | 1997-11-21 | 1999-06-03 | Smithkline Beecham Corporation | Novel cannabinoid receptor modulators |
ATE251103T1 (de) | 1998-04-03 | 2003-10-15 | Yissum Res Dev Co | Synthetische endogene cannabinoidanaloge und ihre verwendungen |
EP1076653B1 (de) | 1998-05-04 | 2004-09-29 | The University of Connecticut | Selektiv auf den cb2-rezeptor wirkende cannabinoide |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
AU4013500A (en) | 1999-07-28 | 2001-02-19 | Ewonders.Com | Dynamic data gathering markup language |
CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
US6448288B1 (en) | 2000-05-17 | 2002-09-10 | University Of Massachusetts | Cannabinoid drugs |
WO2001097793A2 (en) | 2000-06-23 | 2001-12-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
FR2816938B1 (fr) * | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
US20020077322A1 (en) | 2000-12-15 | 2002-06-20 | Ayoub George S. | Protection of neurons against glutamate-induced damage in glaucoma and other conditions |
US20020111377A1 (en) | 2000-12-22 | 2002-08-15 | Albany College Of Pharmacy | Transdermal delivery of cannabinoids |
CA2443105C (en) * | 2001-04-06 | 2011-11-08 | The Board Of Trustees Of The University Of Illinois | Functional role for cannabinoids in autonomic stability during sleep |
ATE394124T1 (de) * | 2002-06-06 | 2008-05-15 | Yissum Res Dev Co | Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums |
WO2004078261A1 (en) * | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
-
2003
- 2003-06-08 AT AT03727927T patent/ATE394124T1/de not_active IP Right Cessation
- 2003-06-08 EP EP03727927A patent/EP1509250B1/de not_active Expired - Lifetime
- 2003-06-08 DE DE60320784T patent/DE60320784D1/de not_active Expired - Lifetime
- 2003-06-08 JP JP2004572061A patent/JP2006517194A/ja active Pending
- 2003-06-08 WO PCT/IL2003/000480 patent/WO2004103410A1/en active IP Right Grant
- 2003-06-08 AU AU2003233172A patent/AU2003233172A1/en not_active Abandoned
-
2004
- 2004-12-06 US US11/003,939 patent/US7749953B2/en not_active Expired - Fee Related
-
2010
- 2010-02-23 US US12/710,540 patent/US20100222438A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1509250B1 (de) | 2008-05-07 |
EP1509250A1 (de) | 2005-03-02 |
WO2004103410A1 (en) | 2004-12-02 |
EP1509250A4 (de) | 2005-08-17 |
AU2003233172A1 (en) | 2004-12-13 |
US20050137159A1 (en) | 2005-06-23 |
JP2006517194A (ja) | 2006-07-20 |
US20100222438A1 (en) | 2010-09-02 |
US7749953B2 (en) | 2010-07-06 |
ATE394124T1 (de) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60320784D1 (de) | Stände zur modulierung des knochenwachstums | |
GEP20074078B (en) | Fluoro substituted cyclo-alkanoindoles, compositions comprising them and their use | |
ATE311363T1 (de) | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
BR0011172A (pt) | Derivados do 4,5-diaril-3(2h)-furanona como inibidores de cliclooxigenase-2 | |
EP1474687A4 (de) | Marks als modifikatoren des p53-pfades und anwendungsverfahren | |
UY27362A1 (es) | Métodos de usar inhibidores de epóxido hidrolasa soluble | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
ATE485366T1 (de) | Verwendung von lysyloxydase inhibitoren zur zellkultur und gewebeaufbau | |
BRPI0414593A (pt) | derivados de ácido sulfonamida substituìda-indol-2-carboxìlico como inibidores de pai-1 | |
MA28279A1 (fr) | Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2 | |
NO20056161L (no) | Formuleringer for behandling av artrittilstander | |
DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
MA27880A1 (fr) | Derives de tetrahydrocarbazole et leur utilisation pharmaceutique | |
WO2003103581A3 (en) | COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION | |
ATE232873T1 (de) | Phosphonsaürederivate als ptp-1b-inhibitoren | |
MX2007002833A (es) | Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios. | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
DE60230990D1 (de) | Zellkulturmethode zur erzeugung von prostata-ähnlichen acini | |
ATE489974T1 (de) | Isoliertes naturidentisches kollagen | |
MY138550A (en) | Method for synthesis of perindopril and its pharmaceutically acceptable salts | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
EA200501557A1 (ru) | Новый способ синтеза (2s)-индолин-2-карбоновой кислоты и использование в синтезе периндоприла | |
DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |